The estimated Net Worth of Douglas W. Pagan is at least $1.02 Milione dollars as of 15 December 2021. Mr. Pagan owns over 2,050 units of Dicerna Pharmaceuticals Inc stock worth over $320,169 and over the last 10 years he sold DRNA stock worth over $698,009. In addition, he makes $0 as Chief Financial Officer at Dicerna Pharmaceuticals Inc.
Douglas has made over 11 trades of the Dicerna Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,050 units of DRNA stock worth $78,351 on 15 December 2021.
The largest trade he's ever made was selling 16,291 units of Dicerna Pharmaceuticals Inc stock on 5 February 2018 worth over $231,658. On average, Douglas trades about 2,333 units every 71 days since 2015. As of 15 December 2021 he still owns at least 8,377 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Mr. Pagan stock trades at the bottom of the page.
Douglas W. Pagan has been appointed as Chief Financial Officer of the Company effective 5/26/2020. Mr. Pagán currently serves as the chief financial officer and secretary of KSQ Therapeutics, Inc. since April 2019. Prior to joining KSQ Therapeutics, Inc., Mr. Pagán was the chief financial officer of Paratek Pharmaceuticals, Inc. from December 2014 through April 2019. Prior to that, from April 2008 to December 2014, Mr. Pagán served as the Vice President of Finance at Acceleron Pharma, Inc. Prior to working at Acceleron, Mr. Pagán served in strategic and financial management roles at Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán worked in healthcare investment banking at J.P. Morgan, as well as pharmaceutical operational roles at Johnson & Johnson. Mr. Pagán received his B.S.E. in Chemical Engineering from Princeton University and his M.B.A. from Columbia Business School.
Douglas Pagan is 48, he's been the Chief Financial Officer of Dicerna Pharmaceuticals Inc since 2020. There are 13 older and no younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
Douglas's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo e Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: